Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow (PubMed:34330755, PubMed:8627166). Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration (PubMed:20172905).
Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling (PubMed:8627166). If this negative signaling from is of sufficient strength, apoptosis of the B-cell can be induced (PubMed:20516366)
Predominantly monomer of isoform CD22-beta. Also found as heterodimer of isoform CD22-beta and a shorter isoform. Interacts with PTPN6/SHP-1, LYN, SYK, PIK3R1/PIK3R2 and PLCG1 upon phosphorylation.
Interacts with GRB2, INPP5D and SHC1 upon phosphorylation (By similarity). May form a complex with INPP5D/SHIP, GRB2 and SHC1
B-lymphocytes
Contains 4 copies of a cytoplasmic motif that is referred to as the immunoreceptor tyrosine-based inhibitor motif (ITIM). This motif is involved in modulation of cellular responses. The phosphorylated ITIM motif can bind the SH2 domain of several SH2-containing phosphatases
No mutation information available.
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to CD22, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 169
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT03682796 | Lymphoma, Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell, Lymphoma, Marginal Zone, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular | Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma | PHASE1 | COMPLETED |
| NCT05223686 | Acute Lymphoblastic Leukemia | To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL. | PHASE1 | UNKNOWN |
| NCT07135466 | B Cell Malignancies | A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies | PHASE1, PHASE2 | RECRUITING |
| NCT04648475 | Leukemia, B-cell, Lymphoma, B-Cell | Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma | PHASE1, PHASE2 | UNKNOWN |
| NCT07109219 | B-cell Acute Lymphoblastic Leukemia (B-ALL) | Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia | PHASE1, PHASE2 | RECRUITING |
| NCT07108868 | Lymphoma, CLL, Acute Lymphoblastic Leukemia, Pediatric | A Phase I Dose Finding Study of MB-CART2219.1 | PHASE1 | RECRUITING |
| NCT07094477 | Lymphoma | Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma | PHASE2 | ACTIVE_NOT_RECRUITING |
| NCT01562990 | Diffuse Large B-Cell Lymphoma | Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse | PHASE1, PHASE2 | COMPLETED |
| NCT05432882 | B Cell Malignancies | CD19/22 Bi-specific CAR-T Cell Therapy | PHASE1, PHASE2 | RECRUITING |
| NCT04715217 | Lymphoma, B-Cell | Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma | PHASE1, PHASE2 | UNKNOWN |